OP0137 EFFICACY AND SAFETY OF TELITACICEPT, A NOVEL BLYS/APRIL DUAL INHIBITOR, IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED 52-WEEK STUDY
L. Wang, Jiatong Li, Dong Xu, Jianmin Fang, Ronald van Vollenhoven, F. Zhang
Topics & Concepts
MedicineB-cell activating factorClinical endpointInternal medicinePlaceboGastroenterologyRandomized controlled trialBlisibimodPlacebo-controlled studyAdverse effectLupus erythematosusSystemic lupus erythematosusImmunologyB cellAntibodyDouble blindDiseasePathologyAlternative medicineSystemic Lupus Erythematosus ResearchMonoclonal and Polyclonal Antibodies ResearchAtherosclerosis and Cardiovascular Diseases